Curis Management

Management criteria checks 3/4

Curis' CEO is Jim Dentzer, appointed in Sep 2018, has a tenure of 5.58 years. total yearly compensation is $1.66M, comprised of 38.1% salary and 61.9% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth €83.77K. The average tenure of the management team and the board of directors is 4.7 years and 9.7 years respectively.

Key information

Jim Dentzer

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage	38.1%
CEO tenure	5.6yrs
CEO ownership	0.1%
Management average tenure	4.7yrs
Board average tenure	9.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jim Dentzer's remuneration changed compared to Curis's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$2m	US$634k	-US$47m
Sep 30 2023	n/a	n/a	-US$47m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$3m	US$615k	-US$57m
Sep 30 2022	n/a	n/a	-US$59m
Jun 30 2022	n/a	n/a	-US$57m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$3m	US$590k	-US$45m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$2m	US$545k	-US$30m
Sep 30 2020	n/a	n/a	-US$31m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$2m	US$510k	-US$32m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$32m
Dec 31 2018	US$2m	US$479k	-US$33m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$43m
Mar 31 2018	n/a	n/a	-US$48m
Dec 31 2017	US$2m	US$443k	-US$53m

Compensation vs Market: Jim's total compensation ($USD1.66M) is above average for companies of similar size in the German market ($USD406.04K).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.

CEO

Jim Dentzer (56 yo)

5.6yrs

Tenure

US$1,662,978

Compensation

Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Dentzer	President	5.6yrs	US$1.66m	0.10% $ 83.8k
Diantha Duvall	CFO and Principal Financial & Accounting Officer	1.7yrs	US$1.01m	0.011% $ 8.9k
Jonathan Zung	Chief Development Officer	less than a year	US$1.04m	0% $ 0
Mark Noel	Vice President of Technology Management & Intellectual Property	15.6yrs	US$413.39k	no data
Elif McDonald	VP of Investor Relations & Corporate Communications	no data	no data	no data
Reinhard von Roemeling	Senior Vice President of Clinical Development	4.7yrs	no data	no data

4.7yrs

Average Tenure

56.5yo

Average Age

Experienced Management: CUS0's management team is considered experienced (4.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
James Dentzer	President	5.6yrs	US$1.66m	0.10% $ 83.8k
Martyn Greenacre	Independent Chairman of the Board	24.2yrs	US$158.70k	0.022% $ 18.0k
Marc Rubin	Independent Director	13.8yrs	US$123.70k	0.024% $ 19.8k
Kenneth Kaitin	Independent Director	20.4yrs	US$126.20k	0.024% $ 19.4k
John Hohneker	Independent Director	2.3yrs	US$106.20k	0% $ 0
Anne Borgman-Hagey	Independent Director	1.5yrs	US$103.70k	0% $ 0

9.7yrs

Average Tenure

65.5yo

Average Age

Experienced Board: CUS0's board of directors are considered experienced (9.7 years average tenure).

Curis Management

Management criteria checks 3/4

Key information

Recent management updates

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc., Annual General Meeting, May 26, 2022

Recent updates

Curis, Inc., Annual General Meeting, May 21, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$8.96 loss per share (vs US$12.14 loss in FY 2022)

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2022)

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$0.61 loss per share (vs US$0.50 loss in FY 2021)

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2021)

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 2Q 2021)

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021)

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2020)

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.28 loss in 1Q 2020)

Curis Receives U.S. Food and Drug Administration Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS

Full year 2020 earnings released: US$0.61 loss per share (vs US$0.97 loss in FY 2019)

Curis, Inc. to Report Q4, 2020 Results on Mar 16, 2021

Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Curis Announces Initiation of Investigator-Sponsored Phase 2 Lucas Study of Ca-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

New 90-day high: €7.25

New 90-day high: €6.70

Curis, Inc. has completed a Follow-on Equity Offering in the amount of $147.500001 million.

Curis, Inc. Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

New 90-day high: €1.17

Third quarter 2020 earnings released: US$0.11 loss per share

Curis, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Curi Announces Appointment of Jason Sandner as its Next Chief Executive Officer, Effective July 1, 2021

Curis, Inc. Announces Abstract for CI-8993 Accepted for Presentation At the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting

New 90-day low - €0.74

First half earnings released

Curis, Inc. has completed a Follow-on Equity Offering in the amount of $17.5 million.

Curis, Inc. to Report Q2, 2020 Results on Aug 04, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age